Tim M. Mayleben
2012 - Vericel
In 2012, Tim M. Mayleben earned a total compensation of $1.3M as Former President and CEO at Vericel, a 22% decrease compared to previous year.
Compensation breakdown
| Option Awards | $875,214 |
|---|---|
| Salary | $407,292 |
| Other | $44,385 |
| Total | $1,326,891 |
Mayleben received $875.2K in option awards, accounting for 66% of the total pay in 2012.
Mayleben also received $407.3K in salary and $44.4K in other compensation.
Rankings
In 2012, Tim M. Mayleben's compensation ranked 5,023rd out of 11,487 executives tracked by ExecPay. In other words, Mayleben earned more than 56.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,023 out of 11,487 | 56th |
Division Manufacturing | 1,758 out of 4,253 | 59th |
Major group Chemicals And Allied Products | 420 out of 1,203 | 65th |
Industry group Drugs | 272 out of 925 | 71st |
Industry Biological Products, Except Diagnostic Substances | 46 out of 165 | 72nd |
Source: SEC filing on October 21, 2014.
Mayleben's colleagues
We found four more compensation records of executives who worked with Tim M. Mayleben at Vericel in 2012.
News
Landos Biopharma CEO Gregory Oakes receives $1.8M in 2022
April 19, 2023
Landos Biopharma Executive Vice President of Operations Jyoti RAC's 2021 pay jumps 195% to $2.8M
April 28, 2022
Esperion Therapeutics CEO Tim Mayleben's 2021 pay rises 19% to $8.2M
April 14, 2022
Esperion Therapeutics CEO Tim Mayleben's 2019 pay falls 89% to $1.1M
April 16, 2020
Esperion Therapeutics CEO Tim Mayleben's 2018 pay jumps 94% to $9.7M
April 18, 2019